Related Experiment Video

Updated: Jul 11, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

[Expression and significance of TRAF4 protein in breast carcinoma]

Wen-Bo Dai1, Ying-Wei Zheng, Xiao-Yi Mi

  • 1Department of Pathology, China Medical University, Shenyang, Liaoning, 110001, P. R. China.

AI Zheng = Aizheng = Chinese Journal of Cancer
|October 12, 2007
PubMed
Abstract

Insights

Tumor necrosis factor receptor-associated factor 4 (TRAF4) nuclear expression decreases in breast cancer, correlating with invasiveness. This finding clarifies TRAF4 roles in breast carcinoma progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Context:

  • Breast cancer pathogenesis involves complex molecular signaling pathways.
  • Tumor necrosis factor receptor-associated factor 4 (TRAF4) expression in breast cancer remains a subject of debate.
  • Understanding TRAF4's role is crucial for developing targeted therapies.

Purpose:

  • To investigate the expression patterns of TRAF4 in normal breast tissue, breast carcinoma, and distinct breast cancer cell lines.
  • To correlate TRAF4 expression levels with the invasive potential of breast cancer cells.

Summary:

  • TRAF4 expression was analyzed in 70 breast carcinoma and 14 normal breast tissue samples using immunohistochemistry.
  • Western blot assessed TRAF4 protein levels in high-invasive (MDA-MB-231) and low-invasive (MCF-7) breast cancer cell lines.
  • Nuclear TRAF4 expression was significantly reduced in non-invasive and invasive ductal carcinomas compared to normal breast tissue, with a further decrease in invasive types.

Impact:

  • The study reveals a significant suppression of nuclear TRAF4 expression in breast carcinoma.
  • Reduced nuclear TRAF4 correlates with increased breast cancer invasiveness.
  • These findings contribute to understanding TRAF4's function in breast cancer progression and may inform future therapeutic strategies.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...